Comparison of MicroRNAs Mediated in Reactivation of the γ-Globin in β-Thalassemia Patients, Responders and Non-Responders to Hydroxyurea

References

• Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: prospects for new therapies for the β-globin disorders. Blood. 2012;120(15):2945–253.
   PubMed Web of Science ®Google Scholar
• Galanello R, Cao A. Relationship between genotype and phenotype. Ann NY Sci. 1998;850:325–333.
   PubMed Web of Science ®Google Scholar
• Bank A. Regulation of human fetal hemoglobin: new players, new complexities. Blood. 2006;107(2):435–443.
   PubMed Web of Science ®Google Scholar
• Alter BP. Fetal erythropoiesis in stress hematopoiesis. Exp Hematol. 1979;7(suppl 5):200–209.
   PubMed Web of Science ®Google Scholar
• Stamatoyannopoulos G, Veith R, Galanello R, et al. Hb F production in stressed erythropoiesis: observations and kinetic models. Ann NY Acad Sci. 1985;445:188–197.
   PubMed Web of Science ®Google Scholar
• Fibach E, Bianchi N, Borgatti M, et al. Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells. Blood. 2003;102(4):1276–1281.
   PubMed Web of Science ®Google Scholar
• Mischiati C, Sereni A, Lampronti I, et al. Rapamycin-mediated induction of γ-globin mRNA accumulation in human erythroid cells. Br J Haematol. 2004;126(4):612–621.
   PubMed Web of Science ®Google Scholar
• Zargari O, Kimyai-Asadi A, Jafroodi M. Cutaneous adverse reactions to hydroxyurea in patients with intermediate thalassemia. Pediatr Dermatol. 2004;21(6):633–635.
   PubMed Web of Science ®Google Scholar
• Panigrahi I, Dixit A, Arora S, et al. Do α deletions influence hydroxyurea response in thalassemia intermedia? Hematology. 2005;10(1):61–63.
   PubMed Web of Science ®Google Scholar
• Mancuso A, Maggio A, Renda D, et al. Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. Br J Haematol. 2006;133(1):105–106.
   PubMed Web of Science ®Google Scholar
• Yavarian M, Karimi M, Bakker E, et al. Response to hydroxyurea treatment in Iranian transfusion-dependent β-thalassemia patients. Haematologica. 2004;89(10):1172–1178.
   PubMed Web of Science ®Google Scholar
• Bunn F. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997;337(11):762–769.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. the Investigators of the multicenter study of hydroxyurea in sickle cell anemia. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322.
   PubMed Web of Science ®Google Scholar
• Costa FC, Fedosyuk H, Neades R, et al. Induction of fetal hemoglobin in vivo mediated by a synthetic γ-globin zinc finger activator. Anemia. 2012;2012:507894. doi: 10.1155/2012/507894.
   PubMedGoogle Scholar
• Lou TF, Singh M, Mackie A, et al. Hydroxyurea generates nitric oxide in human erythroid cells: mechanisms for γ-globin gene activation. Exp Biol Med. 2009;234(11):1374–1382.
   PubMed Web of Science ®Google Scholar
• Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol. 2005;27(7):380–385.
   PubMed Web of Science ®Google Scholar
• Atweh G, Fathallah H. Pharmacologic induction of fetal hemoglobin production. Hematol Oncol Clin North Am. 2010;24:1131–1144.
   PubMed Web of Science ®Google Scholar
• Bissels U, Bosio A, Wagner W. MicroRNAs are shaping the hematopoietic landscape. Haematologica. 2012;97(2):160–167.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–233.
   PubMed Web of Science ®Google Scholar
• Byon JC, Papayannopoulou T. MicroRNAs: allies or foes in erythropoiesis? J Cell Physiol. 2012;227(1):7–13.
   PubMed Web of Science ®Google Scholar
• Bianchi N, Zuccato C, Finotti A, et al. Involvement of miRNA in erythroid differentiation. Epigenomics. 2012;4(1):51–65.
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Menne TF, Scepanovic D, et al. MicroRNA-15a and-16-1 act via MYB to elevate fetal hemoglobin expression in human trisomy 13. Proc Natl Acad Sci USA. 2011;108(4):1519–1524.
   PubMed Web of Science ®Google Scholar
• Dixit A, Chatterjee TC, Mishra P, et al. Hydroxyurea in thalassemia intermedia – A promising therapy. Ann Hematol. 2005;84(7):441–446.
   PubMed Web of Science ®Google Scholar
• Kosaryan M, Vahidshahi K, Karami H, et al. Effect of hydroxyurea on thalassemia major and thalassemia intermedia in Iranian patients. Pak J Med Sci. 2009;25(1):74–78.
   Web of Science ®Google Scholar
• Pourfarzad F, von Lindern M, Azarkeivan A, et al. Hydroxyurea responsiveness in β-thalassemic-patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica. 2012;98(5):696–704.
   PubMed Web of Science ®Google Scholar
• Rivella S. β-Thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica. 2015;100(4):418–430.
   PubMed Web of Science ®Google Scholar
• Naghmi A, Tazeen A, Hamza C, et al. Treatment response to hydroxyurea in β thalassemia. J Islamabad Med Dental College. 2014:3(2):48–52.
   Google Scholar
• Thein SL. β-Thalassaemia prototype of a single gene disorder with multiple phenotypes. Int J Hematol. 2002;76(Suppl 2):96–104.
   PubMed Web of Science ®Google Scholar
• Blau CA, Constantoulakis P, al-Khatti A, et al. Fetal hemoglobin in acute and chronic states of erythroid expansion. Blood. 1993;81(1):227–233.
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843–854.
   PubMed Web of Science ®Google Scholar
• Bissels U, Bosio A, Wagner W. MicroRNAs are shaping the hematopoietic landscape. Haematologica. 2012;97(2):160–167.
   PubMed Web of Science ®Google Scholar
• Zhang L, Sankaran VG, Lodish HF. MicroRNAs in erythroid and megakaryocytic differentiation and megakaryocyte–erythroid progenitor lineage commitment. Leukemia. 2012;26(11):2310–2316.
   PubMed Web of Science ®Google Scholar
• Kouhkan F, Hafizi M, Mobarra N, et al. miRNAs: a new method for erythroid differentiation of hematopoietic stem cells without the presence of growth factors. Appl Biochem Biotechnol. 2014;172(4):2055–2069.
   PubMed Web of Science ®Google Scholar
• Lu J, Guo S, Ebert BL, et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell. 2008;14(4):843–853.
   Web of Science ®Google Scholar
• Schaar DG, Medina DJ, Moore DF, et al. miR-320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation. Exp Hematol. 2009;37(2):245–255.
   PubMed Web of Science ®Google Scholar
• Chen S-Y, Wang Y, Telen MJ, et al. The genomic analysis of erythrocyte microRNA expression in sickle cell diseases. PLoS One. 2008;3(6):e2360. doi: 10.1371/journal.pone.0002360.
   PubMed Web of Science ®Google Scholar
• Azzouzi I, Moest H, Winkler J, et al. MicroRNA-96 directly inhibits γ-globin expression in human erythropoiesis. PLoS One. 2011;6(7):e22838. doi: 10.1371/journal.pone.0022838.
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;322(5909):1839–1842.
   PubMed Web of Science ®Google Scholar
• Sankaran VG, Xu J, Ragoczy T, et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature. 2009;460(7259):1093–1097.
   PubMed Web of Science ®Google Scholar
• Thein SL, Menzel S, Peng X, et al. Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults. Proc Natl Acad Sci USA. 2007;104(27):11346–11351.
   PubMed Web of Science ®Google Scholar
• Sankaran VG. Target therapeutic strategies for fetal hemoglobin induction. Hematol Am Soc Hematol Educ Program. 2011:459–465.
   PubMed Web of Science ®Google Scholar
• Lulli V, Romania P, Morsilli O, et al. MicroRNA-486-3p regulates γ-globin expression in human erythroid cells by directly modulating BCL11A. PLoS One. 2013;8(4):e60436. doi: 10.1371/journal.pone.0060436.
   PubMed Web of Science ®Google Scholar
• Bianchi N, Zuccato C, Lampronti I, et al. Expression of miR-210 during erythroid differentiation and induction of γ-globin gene expression. BMB Rep. 2009;31;42(8):493–499.
   PubMed Web of Science ®Google Scholar
• Bavelloni A, Poli A, Fiume Fiume R, et al. PLCβ1 regulates the expression of miR-210 during mithramycin-mediated erythroid differentiation in K562 cells. Oncotarget. 2014;5(12):4222–4231.
   PubMed Web of Science ®Google Scholar
• Sarakul O, Vattanaviboon P, Tanaka Y, et al. Enhanced erythroid cell differentiation in hypoxic condition is in part contributed by miR-210. Blood Cells Mol Dis. 2013;51(2):98–103.
   PubMed Web of Science ®Google Scholar
• Sawant M, S C, Colah R, et al. Does Hb F induction by hydroxycarbamide work through MIR210 in sickle cell anaemia patients? Br J Haematol. 2016;173(5):801–803.
   PubMed Web of Science ®Google Scholar
• Bianchi N, Finotti A, Ferracin M, et al. Increase of microRNA-210, decrease of raptor gene expression and alteration of mammalian target of rapamycin regulated proteins following mithramycin treatment of human erythroid cells. PLoS One. 2015;10(4):e0121567. doi: 10.1371/journal.pone.0121567.
   PubMed Web of Science ®Google Scholar
• Huang X, Ding L, Bennewith KL, et al. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Molec Cell. 2009;35(6):856–867.
   PubMed Web of Science ®Google Scholar
• Kulshreshtha R, Ferracin M, Wojcik SE, et al. A MicroRNA signature of hypoxia. Mol Cell Biol. 2007;27(5):1859–1867.
   PubMed Web of Science ®Google Scholar
• Hossein Emami SA, Mohammadi Sh, Kavyani S, et al. Investigating the relationship between miR210 upregulation and hemoglobin γ chain expression. Payavard Salamat. 2011;5(3):20–26.
   Google Scholar
• Rogers HM, Yu X, Wen J, et al. Hypoxia alters progression of the erythroid program. Exp Hematol. 2008;36(1):17–27.
   PubMed Web of Science ®Google Scholar
• Mabaera R, West RJ, Conine SJ, et al. A cell stress signaling model of fetal hemoglobin induction: what doesn’t kill red blood cells may make them stronger. Exp Hematol. 2008;36(9):1057–1072.
   PubMed Web of Science ®Google Scholar